Folger Nolan Fleming Douglas Capital Management Inc. Has $10.58 Million Position in Abbott Laboratories $ABT

Folger Nolan Fleming Douglas Capital Management Inc. raised its position in Abbott Laboratories (NYSE:ABT) by 5.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 103,015 shares of the healthcare product maker’s stock after purchasing an additional 5,637 shares during the period. Abbott Laboratories makes up about 0.9% of Folger Nolan Fleming Douglas Capital Management Inc.’s investment portfolio, making the stock its 29th biggest holding. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Abbott Laboratories were worth $10,577,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Cornerstone Financial Management LLC bought a new stake in shares of Abbott Laboratories in the 4th quarter valued at $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter worth about $25,000. Portfolio Resources Advisor Group Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at about $26,000. Finally, Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the fourth quarter worth about $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Down 1.4%

NYSE:ABT opened at $92.78 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market cap of $161.60 billion, a PE ratio of 25.99, a PEG ratio of 1.62 and a beta of 0.63. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The stock has a 50-day simple moving average of $89.03 and a 200 day simple moving average of $105.07.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the previous year, the business posted $1.09 EPS. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The U.S. Justice Department reportedly closed its criminal probe into Abbott’s baby formula operations and chose not to pursue criminal charges, which removes a major overhang and reduces the risk of a damaging legal outcome. US DOJ closes criminal probe into Abbott over baby formula plant, WSJ reports
• Positive Sentiment: Abbott’s Medical Devices business is being positioned for another growth phase, with new diabetes, heart rhythm, and electrophysiology products cited as potential drivers ahead of the company’s next earnings update. How Abbott’s Largest Segment Is Preparing for the Next Growth Phase
• Neutral Sentiment: Healthcare stocks were modestly higher late Monday afternoon, but Abbott still lagged peers and underperformed the sector, suggesting the stock’s move was more idiosyncratic than industry-wide. Sector Update: Healthcare Stocks Higher Late Afternoon
• Neutral Sentiment: Market commentary also highlighted Abbott’s baby formula probe being dropped by the DOJ, reinforcing the legal relief narrative, though investors may still wait for clarity on any civil penalties or follow-on costs. Update: Market Chatter: Abbott Laboratories Baby Formula Probe Dropped by DOJ After Years-Long Investigation Into Contamination Risks
• Negative Sentiment: Despite the DOJ news, Abbott’s shares traded lower and underperformed competitors, indicating that investors may be taking profits or focusing on broader concerns around valuation, growth, or lingering legal uncertainty. Abbott Laboratories stock underperforms Monday when compared to competitors

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research analyst reports. Evercore dropped their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Barclays lowered their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research note on Monday, April 20th. TD Cowen dropped their target price on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Royal Bank Of Canada cut their price target on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Finally, Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.30.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.